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Background Outbreaks of equine influenza (EI) in endemic
populations cause disruption and economic loss.
Objectives To identify (i) factors involved in the spread of EI (ii)
virus strains responsible for outbreaks (iii) single radial haemolysis
(SRH) antibody levels correlating with protection against current
virus strains (iv) evidence of vaccination breakdown.
Methods RT-PCR, virus isolation and SRH were carried out on
nasopharyngeal swabs and blood samples collected from horses,
ponies and donkeys on affected premises. Data relating to 629
samples from 135 equidae were analysed.
Results and conclusions Outbreaks were sporadic, self limiting and
associated with the movement of horses. Vaccination status and age
influenced clinical signs of disease while housing and fomites
contributed to virus spread. Subclinical infection as defined as a
horse which tested positive by one or more of the following; RT-
PCR, virus isolation and seroconversion in the absence of clinical
signs, was identified in 9% of animals. Of the horses with up to date
vaccination records 32% developed clinical signs. Vaccine
breakdown occurred among horses vaccinated with all four
commercially available vaccines. Analysis of HA1 sequence data
generated for 26 viruses indicated that they all belonged to clade 2 of
the Florida sublineage. Higher SRH antibody levels were required
for both clinical and virological protection than reported in studies
where vaccine strains were antigenically and genetically similar to
those circulating in the field. The results of this study therefore
support the OIE recommendations that vaccines be updated to
include representatives of both clades of the Florida sublineage.
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Introduction
Equine influenza virus (EIV) a highly contagious respira-
tory pathogen of horses and other equidae is endemic in
Europe and North America, and major outbreaks have
occurred in Asia,1–5 Africa,6,7 Australia8 and South Amer-
ica (http://www.oie.int/wahis/public.php). Two virus sub-
types H7N7 and H3N8 have been isolated in horses, and
for nearly two decades, both virus subtypes co-circulated.
It is now considered, however, that the H7N7 virus first
identified in horses in 19569 is no longer in circulation.10
Since 1979, all outbreaks of equine influenza (EI) for
which virus has been isolated have been caused by the
H3N8 subtype. Both virus subtypes are included in the
majority of commercially available vaccines despite the fact
that the Office International des Epizooties (OIE) stipulate
it is no longer a requirement for vaccines to include a
H7N7 virus.11
Outbreaks of EI occur predominately among na€ıve and
partially immune populations. During the 2-year period
2010–2012, outbreaks were reported in Argentina, Brazil,
Canada, Chile, China, Dominican Republic, France, Germany,
India, Mongolia, Sweden, UAE, United Kingdom, USA and
Uruguay (http://www.aht.org.uk/icc/linksicc.html; http://
www.oie.int/wahis/public.php) in addition to those identi-
fied in Ireland during this study. At a minimum, such
outbreaks result in suboptimal performance, severe disrup-
tion to training schedules and significant economic losses.
The virus infects the ciliated epithelium and impairs
mucociliary clearance which may take several weeks to
recover, even if uncomplicated by secondary bacterial
infection.12 Rest and restriction of horse movement are
essential to the management of clinical cases.13 This can
result in individual racehorses missing important racing
fixtures which may impact on their potential value and that
of their progeny. Where large populations are affected,
betting revenue may decline as a result of the uncertainty
relating to racing form. Continuing to exercise horses
following infection has been demonstrated to exacerbate
the severity of clinical disease and increase weight loss.14 In
a study carried out in the UK, examinations of the network
of contacts between racehorses suggest that the spread of
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infectious diseases such as EI may occur rapidly.15 This is
largely due to the close proximity of horses within yards
and horses from different yards on the training gallops.
During an EI outbreak, which infiltrated the racing
population in Newmarket in 2003, 21 training yards and
over 1300 horses were affected during a 2-month period.16
Equestrian events may also be affected and sometimes
cancelled. During the outbreak in Uruguay in 2012, which
affected over 2000 horses, race meetings were cancelled for
several weeks and movement of horses out of the country
was prohibited (http://www.oie.int/wahis/public.php). Equine
influenza outbreaks also resulted in the cancellation of
equestrian events in Brazil (http://www.oie.int/wahis/public.
php). While mortality is very rarely associated with EI,
more than 40 horses died during an outbreak affecting over
74 000 horses in Mongolia in 2011. Disconcertingly, several
foal deaths were also reported during EI outbreaks in
France during the same year (http://www.oie.int/wahis/
public.php).
Vaccination against EI is an effective method of disease
control and following the introduction of mandatory
vaccination of racehorses in Ireland and the UK in 1981,
no major equestrian event has been cancelled as a result of
the disease.17 The racing authorities in Ireland and the UK
stipulate that the first two doses of primary vaccination be
administered between 21 and 92 days apart followed by a
third vaccine dose 150–215 days after the second vaccina-
tion. Thereafter, annual booster vaccination is required
(http://www.tuftclub.ie; http://www.thejockeyclub.co.uk).
Outbreaks have occurred, however, when the virus circulat-
ing in the field was significantly different from that
contained in the vaccines.16,18,19 The horse industry requires
EI vaccines that prevent both clinical disease (clinical
protection) and virus shedding. The role of subclinically
infected vaccinated horses (horses that are not virologically
protected) in the global spread of EIV is of major concern to
the industry. The importation of such horses in conjunction
with inadequate quarantine procedures has resulted in
several major outbreaks with significant economic conse-
quences. It is estimated that the eradication of EI from
Australia following the importation of a subclinically affected
horse cost in excess of one billion Australian dollars.8
Therefore, in order to maintain the effectiveness of vaccina-
tion, surveillance of EI viruses and prompt updating of
vaccine strains is of fundamental importance. Ireland has an
active EI surveillance programme as does the UK, but in
many other countries, surveillance is inadequate predomi-
nately due to a lack of funding. The aims of this study were
to identify: the factors involved in the spread of EI in a
country where the virus is endemic, the virus strains
responsible for the outbreaks, the single radial haemolysis
(SRH) antibody levels correlating with protection against
current virus strains circulating in the field and any evidence
of vaccination breakdown as defined by disease and/or virus
shedding.
Materials and methods
Sample collection and clinical histories
Nasopharyngeal swabs and clotted blood samples were
submitted to the Irish Equine Centre by veterinary surgeons
attending horses with acute respiratory disease. After collec-
tion, nasopharyngeal swabs were placed in 5 ml of viral
transport medium as previously described.20 Clinical histo-
ries were obtained from the attending veterinary surgeon and
personnel involved in the day-to-day management of the
horses. On the premises where EI was confirmed, morbidity
was defined as the presence of one or more of the three most
common clinical signs associated with influenza, that is,
pyrexia, nasal discharge and coughing. A confirmed case of
EI was defined as a horse which tested positive by one or
more of the following: RT-PCR, virus isolation and sero-
conversion. Following diagnosis, the sampling regime on
affected premises was dictated by the cooperation of the
veterinary surgeon and the owner. The average time between
consecutive samplings was 66  095 days SE. Nasopha-
ryngeal swabs and whole-blood samples were collected on
average 21  004 SE and 26  008 SE times, respectively,
from all horses included in the study.
Real-time RT-PCR
RNA was extracted from 140 ll of nasal secretions using the
QIAamp Viral RNA Mini kit (Qiagen Venlo, Limburg,
Netherland) according to the manufacturer’s instructions.
One-step RT-PCR was performed using a LightCycler RNA
Amplification SYBR Green I Kit (Roche, Burgess Hill, West
Sussex, UK) on a LightCycler 2.0 platform (Roche) as
previously described.21
Virus isolation
RT-PCR positive samples (100 ll) were passaged up to five
times in the allantoic cavities of 9- to 12-day-old embryo-
nated hen’s eggs. Eggs were incubated at 34°C (1°C) for
72 hours and then placed at 4°C (1°C) overnight before
harvesting. The allantoic fluid was tested for haemaggluti-
nating activity using 1% chicken erythrocytes in PBS
according to standard procedure.22
Serological diagnosis
Antibodies against A/eq/Prague/56 (H7N7) and A/eq/Meath/
07 (H3N8) were measured using SRH as previously
described.23 Results were expressed in square millimeter, and
a seroconversion was defined as an increase in SRH of 25 mm2
or 50% whichever was smaller between the paired serum
samples.24 A difference of 25 mm2 or greater between the
H3N8 and H7N7 antibody levels was considered significant.23
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HAI gene sequencing and analysis
The HA1 sequence (1009 bp) of 26 viruses identified during
this study was determined. This included nine viruses
identified in 2010, two viruses identified in 2011 and 15
viruses identified in 2012. The sequence data for 24 of these
viruses were derived from viral RNA extracted from naso-
pharyngeal swabs. Two viruses (A/eq/Carlow/11 and A/eq/
Kilkenny/1/12) required amplification in embryonated hen’s
eggs prior to sequencing. The HA1 gene was amplified by
RT-PCR and sequenced in four separate reactions as
previously described.25 The RT-PCR products were analysed
on a 12% agarose gel stained with SYBR safe DNA gel stain
(Life Technologies, CA, USA) and purified using the
QIAquick PCR Purification Kit (Qiagen). Sequencing was
performed by Qiagen Sequencing Services (Hilden, Ger-
many), and genetic analysis was undertaken with LASERGENE
software (DNAstar, Madison, WI, USA).
HA1 gene sequence analysis
Multiple nucleotide and amino acid alignments were under-
taken using the CLUSTALW2 program26 from the European
Bioinformatics Institute (http://www.ebi.ac.uk/Tools/clu-
stalw2/). The HA1 gene sequences used in phylogenetic
analysis, including the Irish viruses described here, are
obtainable from the NCBI sequence database GenBank
(Table S1). To determine the relationship between EI viruses,
a maximum likelihood phylogenetic tree was constructed.
The appropriate nucleotide model of substitution was
determined using ModelGenerator.27 The optimum model
was found to be HKY + I.28 One hundred bootstrap
replicates were then carried out with the appropriate
nucleotide model using the software program PHYML
(v3.0)29 and summarised using the majority-rule consensus
method.
Statistical analysis
IBM SPSS Statistics 21 (Armonk, NY, USA) was used to
analyse the data. Difference in age between clinically affected
horses and their healthy cohorts was examined using an
independent t-test. Difference in duration of clinical signs
between vaccinated and unvaccinated horses was also
examined using this test. A significance level of P < 005
was used for all statistical tests.
Results
Between November 2010 and October 2012, EI was diagnosed
on nine premises located in five counties in Ireland (Table 1).
Outbreaks occurred on a variety of premises among Thor-
oughbred horses, non-Thoroughbred horses, ponies and
donkeys (Table 1). Initial diagnosis on all premises was made
by RT-PCR. Following diagnosis, all clients in consultation
with their veterinary surgeons agreed to participate in a disease
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investigation. Data relating to 629 samples from 135 equidae
were analysed. Of these, at least 60 (44%) were described as
clinically affected by the person responsible for the day-to-day
management of the horses. A confirmed diagnosis of EI was
made in 60 (44%) of the horses in the study. The vaccination
status of the horses on each of the nine premises is summarised
in Table 1.
Factors involved in the spread of EI
Spread between premises
Eight of the nine outbreaks occurred during the autumn (5)
and winter (3) months. In all premises, EI was diagnosed
following the movement of horses on or off the premises.
Horses on five premises were affected following the intro-
duction of a new arrival of unknown vaccination status
(premises 3, 5, 6, 8, 9). On three premises, clinical signs were
observed following the return of horses from an equestrian
event including a local hunt (premises 1), a show jumping
training show (premises 4) and a non-TB sale (premises 7).
In one racing yard (premises 2), horses were affected
following the return of a horse from another premises. On
six premises where it was presumed that the source of
infection was identified, the incubation period for the index
case ranged from 24 hours to 4 days.
Spread within premises
Housing. Accommodation details are presented in Table 2.
Of the 135 equidae for which this information was available,
68 were housed in barns, 57 were housed in individual
stables, and 10 were at grass. Twenty-nine of the 68 horses
(43%) housed in barns, 29 of the 57 horses (51%) housed in
stables and two of the 10 (20%) horses at grass were
described as clinically affected.
Fomites/personnel. There was evidence to suggest that
horses were infected following exposure to contaminated
fomites or personnel on two premises (1, 3). On premises 1,
a 2-year-old filly that was isolated on her own in a separate
barn following arrival on the premises exhibited clinical signs
4 days after the index case. This horse tested negative by RT-
PCR but subsequently seroconverted. The filly did not have
direct contact with any of the other horses in the yard. On
premises 3, two mares at grass exhibited mild clinical signs
10 days after the index case. Both mares were at grass full
time and had no direct contact with any other horses on the
premises. Both mares tested negative by RT-PCR; however,
one of the mares that was seronegative seroconverted. The
mares had daily contact with handlers from the affected yard.
Aerosol transmission was discounted as the source of
infection as horses in neighbouring fields were not infected.
Clinical signs. Veterinary advice was sought from 48 hours
to 14 days (average 49  125 SE days) after first clinical
signs were observed. Clinical signs most commonly reported
were persistent coughing and nasal discharge. Pyrexia was also
reported in several horses; however, temperature records were
only available on one premises (premises 5). A significant
difference (P = 0000) in age between horses that were
clinically affected (44  044 SE years) and their healthy
(76  056 SE years) cohorts was observed. Evidence of
subclinical infection in 12 horses (9%) on four premises was
established (Table 2). Of these 12 horses, EI was confirmed in
Table 2. Vaccination status, housing type, morbidity, confirmatory diagnoses and subclinical infection
Premise number Vaccination (%)* Housing type (no. equidae) Morbidity (%)
Symptomatic/EI
confirmed Asymptomatic/EI confirmed
1 0 Stable block (5) 2/5 (40) 2/2 0/2
2 44 Stable block (18) 10/18 (56) 6/9 3/9
3 0 Barn (6)
Grass (9)
Stable block (1)
5/6 (83)
2/9 (22)
0/1 (0)
3/3 0/3
4 0 Barn (6) 4/6 (68) 4/4 0/4
5 23 Multiple barns (43) 17/43 (40) 14/21 7/21
6 38 Stable block (16) 3/16 (19) 2/3 1/3
7 0 Stable block (3)
Grass (1)
3/3 (100)
0/1 (0)
3/3 0/3
8 0 Barn (13) 3/13 (23) 3/4 1/4
9 0 Stable block (14) 11/14 (79) 11/11 0/11
EI, equine influenza.
*Up to date vaccination records available.
Gildea et al.
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2 (17%) byRT-PCR and virus isolation, in 2 (17%) byRT-PCR
and serology and in 8 (67%) by serology only.
Serological status and clinical protection
The SRH results for acute serum samples collected from the
60 confirmed cases identified during this study are summar-
ised in Table 3 as is the incidence of clinical signs. Five of the
60 confirmed cases had an up to date vaccination record.
In order to study the level of protection afforded by pre-
existing antibodies, 68 horses were selected on the basis of
having no serological evidence of recent exposure by natural
infection. On examination of their acute serum samples,
these horses were seronegative or had similar H3N8 to H7N7
antibody levels, that is, consistent with exposure to H3N8 by
vaccination. Their clinical and serological status is illustrated
in Figure 1. Of the 36 horses that were seronegative, 29
developed clinical signs. Twenty-eight of these had a
confirmed diagnosis of EI. Of the seven seronegative horses
that did not develop clinical signs, five were at grass
(premises 3) and had no direct contact with infected horses.
Only one of the 32 seropositive horses had antibody levels
<85 mm2. This horse did not develop clinical signs. Nine
horses had antibody levels between 85 and 150 mm2 of
which four became clinically affected and tested positive for
EI. Two of the five horses with antibody levels 85–150 mm2
that did not develop clinical signs also tested positive for EI.
Twenty-two horses had antibodies levels >150 mm2 of which
four were described as clinically affected. Only one of these
tested positive for EI, and this horse had an SRH level of
151 mm2. Three of the remaining 18 horses with antibody
levels >150 mm2 also tested positive.
Effectiveness of vaccination
Of the 60 horses described as clinically affected of which 80%
tested positive for EI, 33 (55%) were reported unvaccinated,
or of unknown vaccination status, 4 (7%) had out-of-date
Figure 1. Percentage and H3N8 SRH level of horses which were clinically affected, clinically affected and equine influenza positive, developed no clinical
signs or were subclinically infected.
Table 3. SRH data of acute serum samples for confirmed equine influenza cases
Premises number No. confirmed cases
Seronegative
H7N7 and H3N8
Seronegative H7N7
Seropositive H3N8
Seropositive
H3N8 > H7N7 Seropositive H3N8 = H7N7
1 2 1/2 1/2 0/2 0/2
2 9 2/9 4/9 0/9 3/9
3 3 3/3 0/3 0/3 0/3
4 4 4/4 0/4 0/4 0/4
5 21 7/21 6/21 1/21 7/21
6 3 1/3 1/3 1/3 0/3
7 3 2/3 1/3 0/3 0/3
8 4 3/4 1/4 0/4 0/4
9 11 5/11 2/11 3/11 1/11
Total (%) 60/135 (44) 28/60 (47) 16/60 (27) 5/60 (8) 11/60 (18)
Clinically affected (%) 48/60 (80) 28/28 (100) 11/16 (69) 4/5 (80) 5/11 (46)
H3N8 > H7N7: H3N8 antibody level >25 mm2 compared with H7N7 antibody level; H3N8 = H7N7: H3N8 antibody level <25 mm2 difference
compared with H7N7 antibody level.
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vaccination records, and the vaccination records of 15 (25%)
horses were unavailable. On premises 2 where clinical signs
were reported among both vaccinated and non-vaccinated
horses, the average duration of clinical signs among vaccinated
horses (80  063 SE days) was significantly less (P = 0028)
than that reported among unvaccinated horses or horses with
unknown/out-of-date vaccinationstatus (126  160 SE days).
On premises 5, booster vaccinations of Duvaxyn IE-T
Plus were given to 11 healthy horses 5 days after first
clinical signs were observed. No new cases were observed
post-vaccination.
Twenty-five horses in this study had up to date vaccination
records, eight of these (32%) developed clinical signs and one
subclinically affected horse shed virus (Table 4). This horse
which was not virologically protected was a vaccinated 2-
year-old in training (premises 2). Two nasopharyngeal swabs
collected 72 hours apart from this horse were RT-PCR and
virus isolation positive despite the absence of clinical signs
(Table 4). Of the 25 horses, four were vaccinated with
ProteqFlu Te which contains H3N8 only and two of these
developed clinical signs. Of the remaining 21 horses which
were vaccinated with products which contained both H7N7
and H3N8 virus, 8 (38%) of these had comparable H3N8 and
H7N7 antibody levels. All eight horses had H3N8 SRH levels
>117 mm2, and six had antibody levels >150 mm2. Only one
of these horses that had a H3N8 SRH level of 118 mm2
developed clinical signs. Five of the 21 horses (24%) had
H3N8 antibody levels that where were >25 mm2 compared
with their H7N7 antibody level. These horses had a mean
H7N7 antibody level of 138  248 mm2 and none devel-
oped clinical signs. Eight of the 21 horses (38%) were H7N7
seronegative but H3N8 seropositive, and four of these
developed clinical signs. One horse which was seronegative
for both subtypes was also clinically affected.
Availability of vaccination records
The vaccination records of 41 horses on five premises (2, 3, 5,
6, 9) were unknown or unavailable. Nine of the 41 (22%)
horses were seronegative for antibodies to H7N7 and H3N8
on initial sampling. Nine (22%) horses were seronegative for
antibodies to H7N7 but seropositive for antibodies to H3N8
on initial testing. Ten of the horses (24%) had H3N8 antibody
levels significantly higher (188  182 mm2 SE) than that of
their H7N7 antibody levels (109  198 mm2 SE). Thirteen
horses (32%) had H7N7 antibodies in acute samples
(166  95 mm2 SE), which were comparable to their H3N8
antibody level (163  87 mm2 SE).
Genetic characterisation and phylogeny
The nucleotide sequence of the HA1 gene of nine viruses
identified on two premises in 2010, two viruses identified on
separate premises in 2011 and 15 viruses identified on five
premises in 2012 was determined. Analysis of the sequence
data generated for the 26 viruses indicated that they all
belonged to clade 2 of the Florida sublineage of the American
lineage (Figure 2). The HA1 nucleotide sequence of nine
viruses identified on two premises in Kildare in November
and December of 2010 was identical. The sequence of five
viruses identified on a single premises in Kilkenny in January
2012 was identical. The sequence of a further 10 viruses
identified on four premises in Cork, Clare and Kildare from
August to October 2012 was also identical. These latter 10
viruses differed from the five viruses identified in January
2012 by a single nucleotide substitution which did not result
in an amino acid change. There was no HA1 nucleotide
sequence difference between RNA extracted directly from
swab material and RNA extracted from allantoic fluid of
infected eggs from samples taken on the same premises (data
not shown).
Table 4. Vaccination breakdown
Vaccine* No. doses
Time since
last vaccination
(months)
Acute SRH
H7N7 (mm2)
Acute SRH
H3N8 (mm2) Clinical signs EI confirmed EI detection method
Equilis Prequenza Te 2 5 106 118 Yes Yes RT-PCR, seroconversion
Equilis Prequenza Te 2 2 Negative Negative Yes Yes RT-PCR, seroconversion
Duvaxyn IE-T Plus 2 4 Negative 146 Yes Yes RT-PCR
ProteqFlu Te 3 5 Negative 32 Yes Yes RT-PCR, seroconversion
ProteqFlu Te 3 7 Negative 127 Yes No N/A
Equilis Prequenza Te 3 9 116 127 No Yes RT-PCR, VI,
seroconversion
Equilis Prequenza Te 3 5 Negative 203 Yes No N/A
Equip FT 5 5 Negative 313 Yes Yes RT-PCR, VI
Duvaxyn IE-T Plus 6 5 Negative 314 Yes No N/A
EI, equine influenza; VI, virus isolation.
*Last vaccine dose.
Gildea et al.
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Amino acid alignment
The HA1 amino acid sequence of EI viruses identified during
this study were aligned with A/eq/Newmarket/5/03, a repre-
sentative virus of the Florida sublineage clade 2, and any
amino acid changes are summarised in Figure 3. The
numbering of the HA1 amino acid sequence starts with the
serine residue immediately downstream of the predicted
signal peptide cleavage site.30 Negative numbers represent the
predicted signal sequence. All Irish viruses identified during
this study belonged to clade 2 of the Florida sublineage and
did not have the two characteristic amino acid substitutions
(V78A and N159S) in putative antigenic sites that distinguish
viruses such as A/eq/Wisconsin/1/03 (clade 1) from the UK
prototype clade 2 virus A/eq/Newmarket/5/03.16 All Irish
viruses had the ‘FNF’ motif at position 11 to 9 first
identified in a UK isolate (A/eq/Newmarket/1/07) in 2007.31
Figure 2. Phylogenetic tree of HA1 nucleotide sequences. Phylogenetic analysis of HA1 nucleotide sequences encoded by EIV, subtype H3N8. Bootstrap
values obtained after 100 replicated are shown at the major nodes. Accession numbers for the genes reported in this manuscript are listed in Table S1.
Red = pre-divergent; blue = Eurasian; black = American; green = Florida sublineage clade 1; pink = Florida sublineage clade 2. A/eq/Kildare/2/10 is
representative of A/eq/Kildare/1/10, A/eq/Kildare/3/10, A/eq/Kildare/4/10, A/eq/Kildare/5/10, A/eq/Kildare/6/10, A/eq/Kildare/7/10, A/eq/Kildare/8/10 and
A/eq/Kildare/9/10; A/eq/Kilkenny/3/12 is representative of A/eq/Kilkenny/1/12, A/eq/Kilkenny/2/12, A/eq/Kilkenny/4/12, A/eq/Kilkenny/5/12; A/eq/Kildare/
2/12 is representative of A/eq/Cork/1/12, A/eq/Cork/2/12, A/eq/Clare/1/12, A/eq/Clare/2/12, A/eq/Clare/3/12, A/eq/Kildare/1/12, A/eq/Kildare/3/12, A/eq/
Kildare/4/12 and A/eq/Kildare/5/12.
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In addition, all Irish viruses had three amino acid substitu-
tions (G7N, P103L and V111I) when compared to A/eq/
Newmarket/5/03. G7N has previously been observed in
viruses identified in Europe, China, Mongolia and
India.4,25,31–33 Within the Irish viruses, a further three amino
acid substitutions occurred, two of which were in antigenic
sites. One of these, A144V, which occurred in A/eq/Carlow/
11, A/eq/Kilkenny/3/12 and A/eq/Kildare/2/12, was in anti-
genic site A.34 A second amino acid change I242T that
occurred in A/eq/Kilkenny/11 was in antigenic site D.34 To
the best of our knowledge, this is the first published report
regarding these two amino acid changes. The third amino
acid change P169H occurred in A/eq/Carlow/11, but was not
in an antigenic site.
Discussion
Equine influenza outbreaks identified during this study were
sporadic and self-limiting and occurred primarily among
equidae which were unvaccinated or did not have up to date
vaccination records. This study included the first-confirmed
case of EI affecting donkeys in Ireland (premises 4). In all
cases, outbreaks occurred following the movement of horses.
On the majority of premises, horses were clinically affected
following the introduction of a new arrival of unknown
vaccination status. The risk associated with failing to isolate
new arrivals and establish their antibody status was high-
lighted previously.20,31,32 The seasonality of the outbreaks
and the contribution of stabling and fomites/personnel to
virus spread were also observed previously as was the influence
of age on the clinical severity of disease.2,6,7,19,20,35,36 However,
the rate of virus isolation was greater than that reported in a
similar study from 2007 to 2010.20 In the current study, virus
was isolated from 18 of the 45 (40%) RT-PCR-positive nasal
swabs which were collected from 14 of the 135 horses. In the
previous study, a delay in veterinary intervention was identi-
fied as a possible contributing factor to the low rate of virus
isolation.20 As a similar delay was observed in the present
study, it is likely that the increased rate of virus isolation was
due to the fact that 10 of the 14 horses were seronegative on
initial sampling. Seronegative horses rapidly amplify and shed
large quantities of virus and are frequently the index case
during outbreaks.37–39
A definite correlation between SRH antibody levels
(H3N8) and protective immunity has been established
following experimental challenge studies and observations
in the field. Horses with antibody levels >85 mm2 are
clinically protected, that is, protected against clinical disease,
and horses with antibody levels >150 mm2 are virologically
protected, that is, protected against infection, provided the
vaccine strains are closely related to those circulating in the
field.24,38,40 It is not possible to differentiate between H3N8
antibodies due to vaccination and natural infection. Other
studies have defined pre-infection antibody titres as those of
blood samples taken the day after influenza was first
diagnosed.16,19 However, delayed veterinary intervention as
observed in previous outbreaks20 affects interpretation of
serological data, as at the time of sample collection, horses
have often mounted an antibody response to the virus that is
circulating on the premises. Thus, it is often not possible to
determine the pre-infection SRH titre that correlates with
protection. In horses vaccinated with the majority of vaccines
which contain the H7N7 subtype, the measurement of
antibodies against H7N7 is a useful aid to the identification
of those horses that have vaccinal rather than post-infection
titres as a higher H3N8 antibody level in comparison with
H7N7 suggests exposure by natural infection.23 In this study,
horses sampled pre-infection were defined as those that were
seronegative or had similar H7N7 and H3N8 antibody titres.
These horses exhibited a strong correlation between their
pre-existing SRH antibody level and susceptibility to influ-
enza as defined by clinical signs and confirmatory laboratory
diagnosis. Seventy-eight per cent of the seronegative horses,
44% of horses with antibody levels of between 85 and
150 mm2 and 5% of horses with antibody levels >150 mm2
developed influenza. No horse with a pre-existing antibody
level >151 mm2 exhibited clinical signs that were confirmed
as EI. No horse with a pre-existing antibody level >210 mm2
tested positive for EI, that is, they were virologically
protected. Subclinical infection was identified in 12 horses
on four different premises. Of the 12 horses, six had antibody
titres consistent with vaccination. The mean H3N8 antibody
titre of these six horses was 175  147 mm2 SE. Virus was
isolated from one of these horses on two occasions 72 hours
apart. This horse which had a H3N8 SRH antibody level of
127 mm2 had received its third vaccine dose (Equilis
Prequenza Te) 9 months prior to the outbreak.
Over 80% of the horses included in this study were
unvaccinated, of unknown/unavailable vaccination status or
their vaccination record was out of date. Furthermore, over
70% of horses that tested positive in this study were
seronegative for H7N7, suggesting no vaccinal antibodies at
Figure 3. HA1 amino acid sequence alignment.
A/eq/Kildare/2/10 is representative of A/eq/Kildare/1/10, A/eq/Kildare/3/10, A/eq/Kildare/4/10, A/eq/Kildare/5/10, A/eq/Kildare/6/10, A/eq/Kildare/7/10, A/
eq/Kildare/8/10 and A/eq/Kildare/9/10; A/eq/Kilkenny/3/12 is representative of A/eq/Kilkenny/1/12, A/eq/Kilkenny/2/12, A/eq/Kilkenny/4/12, A/eq/
Kilkenny/5/12; A/eq/Kildare/2/12 is representative of A/eq/Cork/1/12, A/eq/Cork/2/12, A/eq/Clare/1/12, A/eq/Clare/2/12, A/eq/Clare/3/12, A/eq/Kildare/1/
12, A/eq/Kildare/3/12, A/eq/Kildare/4/12 and A/eq/Kildare/5/12.
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the time of exposure. On three premises, it was reported that
the majority of horses were vaccinated; however, vaccination
records were only available for between 23% and 44% of
horses. Nevertheless, examination of the H7N7 and H3N8
antibody level indicated that horses whose vaccination record
was unknown or unavailable were not necessarily unvacci-
nated and highly susceptible to infection. Some had antibody
levels in excess of 150 mm2.
Of the 25 horses with up to date vaccination records, a
confirmed diagnosis of EI was made in 5 (20%) of 8 (32%)
clinically affected horses. The average time since last
vaccination for the eight clinically affected horses was
48  049 SE months. These horses had been vaccinated
with all four commercially available products, Duvaxyn IE-
T Plus (2), Equip FT (1), Equilis Prequenza Te (3) and
ProteqFlu Te (2). Two of the horses had received their third
vaccine dose of ProteqFlu Te on average 6 months prior to
developing clinical signs. These horses had a mean H3N8
antibody level of 79  473 mm2 SE on initial sampling. A
third horse which had received its second dose of Equilis
Prequenza Te 5 months prior to the outbreak had compa-
rable H7N7 (106 mm2) and H3N8 (118 mm2) antibody
levels, thus suggesting this horse had responded well to
vaccination but was also inadequately protected. The five
remaining horses were all vaccinated with products con-
taining both virus subtypes. They had received on average
36 doses of vaccine and had last been vaccinated between 2
and 5 months prior to developing clinical signs. All were
H7N7 seronegative and one was also H3N8 seronegative,
suggesting these horses had responded poorly to vaccina-
tion. Poor response to vaccination is seen in some horses
and is believed to play an important role in the transmis-
sion of virus among vaccinated horses.24 Two recent
comparative vaccine studies have demonstrated that
between 39% and 43% of Thoroughbred weanlings failed
to seroconvert following first vaccination and that the
incidence of poor responders was shown to be vaccine
related41–42 Poor durability of antibody response between
second and third vaccination and approximately 6 months
following third vaccination have also previously been
reported.37,38,41,43–44
All virus strain identified as being responsible for
outbreaks in Ireland during this study were from the Florida
sublineage clade 2 and were similar to those identified during
previous outbreaks in Ireland in 2007 and 200825 in
Europe31,32 and in Asia.4,33 Experimental challenge studies
and field data have demonstrated that protection against
virus shedding correlates with the degree of antigenic
relatedness between the vaccine and challenge strain.16,19,45
In this study, evidence of vaccine breakdown occurred in
eight horses, six of which had been vaccinated with products
not updated in line with the OIE recommendations of 2004
or 2010. These vaccines contained A/eq/Newmarket/1/93
(Duvaxyn IE-T Plus, Equilis Prequenza Te) and A/eq/
Kentucky/98 (Equip FT) as a representative of the American
lineage. Evidence of vaccine breakdown occurred in a further
two horses vaccinated with ProteqFlu Te. This vaccine has
been updated in line with OIE recommendations from 2004
to include A/eq/Ohio/03 as a representative of clade 1 of the
Florida sublineage; however, it does not include a represen-
tative of clade 2 as recommended by the OIE since 2010.
Cross-protection is the ability of an antigen to elicit a
protective immune response against infection with another
antigen, for example a heterologous strain of virus. The
findings of this study suggest that cross-protectivity between
the viruses included in the current vaccines and the
circulating (field) strains has decreased. Forty-four per cent
and 18% of 68 horses that had pre-infection antibody levels
that correlate with clinical protection and virological pro-
tection with homologous virus developed clinical signs.
Subclinical infection was detected in horses which had a
mean H3N8 SRH antibody level of 175  147 mm2 SE, and
one horse had an SRH level of 210 mm2, that is, a level
higher than that usually elicited by booster vaccination.46
The results of this study therefore suggest that vaccinal
antibody levels indicative of clinical protection against
homologous virus did not correlate with protection against
the clade 2 viruses responsible for these outbreaks.
Equine influenza vaccines are updated to effect qualita-
tive rather than quantitative improvements in the immune
response. Comparative vaccine studies suggest that the level
of antibodies elicited by current vaccines is related to
adjuvant composition rather than antigenic load or virus
strains.41,42,46 When there is mismatch between the
circulating field strains and the vaccine strains, infection
may result in clinical influenza and/or virus shedding
regardless of a high SRH response to vaccination. Replacing
an out-of-date virus in a vaccine with an epidemiologi-
cally relevant strain is unlikely to elicit a greater anti-
body response but should maximise protective immunity
against EI. In order to ensure that mandatory vaccination
programmes provide optimum protection, vaccines must
contain strains that are antigenically similar to those
circulating in the field. The findings of epidemiological
investigations such as this should not be overlooked, and
vaccine strains must be updated in a timely manner as
recommended by the OIE.
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